HOME >> BIOLOGY >> NEWS
First production of a human protein with complex glycosylation in genetically modified yeast

LEBANON, NEW HAMPSHIRE (August 28, 2003): Yeasts and other fungi are reliable, cost-effective workhorses for the production of many industrial enzymes. However, biopharmaceutical companies currently manufacture few human therapeutic proteins using these organisms. The inability to correctly decorate human proteins with complex sugar molecules a process known as glycosylation has been the main obstacle that has prevented the use of fungal hosts for the expression of human therapeutics.

Today a team of scientists at GlycoFi, Inc. and Dartmouth College report the successful reengineering of the glycosylation pathway in the yeast Pichia pastoris. Published in the latest issue of Science, these results constitute the first fungal organism able to secrete a human glycoprotein with complex human glycosylation.

"The vast majority of therapeutic proteins are glycosylated and most require complex, human-like glycosylation to ensure therapeutic efficacy," said GlycoFi's Stephen Hamilton, Ph.D., lead author of the publication. "Mammalian cell lines can replicate human-like glycoprotein processing to a large extent, and so have traditionally been used to produce most protein therapeutics. However, mammalian cell culture systems have significant drawbacks including low protein yields, long fermentation times, production of a mixture of protein glycoforms, and ongoing viral contamination issues."

"Being able to produce human glycoproteins with homogenous N-glycan structures in a fungal host allows us to take advantage of the inherent commercial advantages of yeast and other fungal production systems," says Dr. Tillman Gerngross, GlycoFi chief scientific officer and associate professor of biochemical engineering at Dartmouth College. "Moreover, the ability to produce a homogeneous glycoprotein in yeast offers the biopharmaceutical industry a new tool for further understanding the structure-function relationships of glycoproteins and for potentially crea
'"/>


28-Aug-2003


Page: 1 2 3

Related biology news :

1. First glimpse of DNA binding to viral enzyme
2. First clinical study of new pediatric croup vaccine shows safety, tolerability in adults
3. 2nd media alert First Scientific Conference on Childhood Leukaemia
4. First International Scientific Conference on Childhood Leukaemia
5. First ever standards linking climate change, biodiversity and poverty seek global peer review
6. First genetic comparison of purebred domestic dogs produces surprises
7. First time in the U.S.: Saint Louis University tests third-generation vaccine against smallpox
8. First target for childhood malaria vaccine
9. First study of resveratrol dietary supplement finds effect on breast and prostate cancers unlikely
10. First flavors form a lasting impression
11. STN International launches Derwent World Patents Index First View

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/7/2020)... ... 2020 , ... Nine middle school teachers from eight states ... unique professional development program that provides advanced STEM (science, technology, engineering and math) ... , Created in partnership between the National Stem Cell Foundation and The Gatton ...
(Date:7/31/2020)... ... July 30, 2020 , ... ... Phase II contract awarded by the Joint Science & Technology Office—Chemical and Biological ... is to develop, optimize, and scale-up a highly efficient mammalian cell culture-based bioprocess ...
(Date:7/18/2020)... ... July 16, 2020 , ... ... effectiveness of the Invictus Medical Neoasis™ active noise control device to attenuate typical ... that the Neoasis™ device attenuated the alarm sounds from patient monitors, ventilators and ...
Breaking Biology News(10 mins):
(Date:8/12/2020)... (PRWEB) , ... August 11, ... ... a biopharmaceutical cold chain validation engineering firm, is making available for free ... the need to incorporate concurrent transport simulation testing into today’s biologics licensing ...
(Date:8/7/2020)... ... August 06, 2020 , ... VGXI, a highly ... closed on the purchase of greenfield for a new, expanded manufacturing facility. The ... 21 acres in the initial acquisition, with an option to purchase an additional ...
(Date:8/3/2020)... LEXINGTON, Ky. (PRWEB) , ... August 03, 2020 , ... ... innovative products for transformative growth, , Known as MediVet Biologics ... Health brand. , The new Ardent Animal Health will build on its ...
(Date:7/31/2020)... ... July 29, 2020 , ... ... launch of its new tagline, “BUILDING FOR LIFE.” The adoption of this taglines ... the globe, requiring fast track capacity to provide patients with urgently needed vaccines ...
Breaking Biology Technology:
Cached News: